← Back to Clinical Trials
Recruiting NCT07120048

NCT07120048 Real World Data Collection on the INSPIRIS RESILIA Aortic Valve

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07120048
Status Recruiting
Phase
Sponsor Edwards Lifesciences
Condition Aortic Valve Disease
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2025-07-30
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Edwards INSPIRIS RESILIA Aortic Valve

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2025-07-30 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Collect real-world data on hemodynamic and clinical outcomes of the INSPIRIS RESILIA Aortic Valve, Model 11500A, in subjects requiring replacement of their native or prosthetic aortic valve as the only heart valve procedure during the index procedure, with or without other concomitant procedures.

Eligibility Criteria

Inclusion Criteria: 1. Patients requiring an aortic valve replacement using the INSPIRIS RESILIA aortic valve according to its intended purpose 2. Patients with standard-of-care pre-procedure imaging evaluation (echocardiography and CT) data available 3. Age ≥ 18 years 4. Provision of written informed consent Exclusion Criteria: 1. Active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to the scheduled aortic valve replacement surgery 2. Emergency procedure 3. Patients requiring a non-aortic heart valve procedure during the index procedure

Contact & Investigator

Central Contact

Sabrina Hundt, PhD

✉ sabrina_hundt@edwards.com

📞 +49 151 67550601

Principal Investigator

Torsten Doenst, Prof. Dr. med.

PRINCIPAL INVESTIGATOR

Jena University Hospital, University of Jena

Frequently Asked Questions

Who can join the NCT07120048 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Valve Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07120048 currently recruiting?

Yes, NCT07120048 is actively recruiting participants. Contact the research team at sabrina_hundt@edwards.com for enrollment information.

Where is the NCT07120048 trial being conducted?

This trial is being conducted at Heidelberg, Germany, Bad Neustadt an der Saale, Germany, Erlangen, Germany, Munich, Germany and 10 additional locations.

Who is sponsoring the NCT07120048 clinical trial?

NCT07120048 is sponsored by Edwards Lifesciences. The principal investigator is Torsten Doenst, Prof. Dr. med. at Jena University Hospital, University of Jena. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology